These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 17197488)

  • 21. [Phosphodiesterase-5 inhibitor with broad temporal effectiveness window].
    MMW Fortschr Med; 2004 Apr; 146(16):62. PubMed ID: 15222506
    [No Abstract]   [Full Text] [Related]  

  • 22. Salvage techniques for phosphodiesterase 5 inhibitor therapy: purposeful but how much?
    Burnett AL
    Eur Urol; 2006 Jul; 50(1):29-30. PubMed ID: 16567036
    [No Abstract]   [Full Text] [Related]  

  • 23. Sildenafil citrate therapy for pulmonary arterial hypertension.
    Hoeper MM; Welte T
    N Engl J Med; 2006 Mar; 354(10):1091-3; author reply 1091-3. PubMed ID: 16525151
    [No Abstract]   [Full Text] [Related]  

  • 24. Hypertrophied right hearts get two for the price of one: can inhibiting phosphodiesterase type 5 also inhibit phosphodiesterase type 3?
    Kass DA
    Circulation; 2007 Jul; 116(3):233-5. PubMed ID: 17638937
    [No Abstract]   [Full Text] [Related]  

  • 25. Efficacy of PDE-5-inhibitors for erectile dysfunction. A comparative meta-analysis of fixed-dose regimen randomized controlled trials administering the International Index of Erectile Function in broad-spectrum populations.
    Rosen RC; Shaw JW
    Int J Impot Res; 2006; 18(6):570-1; author reply 572-3. PubMed ID: 17075585
    [No Abstract]   [Full Text] [Related]  

  • 26. Improvement of mortality by long-term E4010 treatment in monocrotaline-induced pulmonary hypertensive rats.
    Kodama K; Adachi H
    J Pharmacol Exp Ther; 1999 Aug; 290(2):748-52. PubMed ID: 10411587
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Chronic treatment with PDE-5 inhibitors is there anything more than treating erectile dysfunction?].
    Vela Navarrete R; García Cardoso JV; López Farre A; Quesada Romero P; Pardo Montero M
    Actas Urol Esp; 2007 Mar; 31(3):179-84. PubMed ID: 17658146
    [No Abstract]   [Full Text] [Related]  

  • 28. Emergence and success of PDE5 inhibitors as effective therapy for erectile dysfunction.
    Manganiello V
    Int J Impot Res; 2004 Jun; 16 Suppl 1():S1-3. PubMed ID: 15224126
    [No Abstract]   [Full Text] [Related]  

  • 29. Potency, selectivity, and consequences of nonselectivity of PDE inhibition.
    Bischoff E
    Int J Impot Res; 2004 Jun; 16 Suppl 1():S11-4. PubMed ID: 15224129
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effectiveness duration determines selection].
    MMW Fortschr Med; 2006 Jul; 148(29-30):54-5. PubMed ID: 16910411
    [No Abstract]   [Full Text] [Related]  

  • 31. Transient global amnesia after intake of tadalafil, a PDE-5 inhibitor: a possible association?
    Schiefer J; Sparing R
    Int J Impot Res; 2005; 17(4):383-4. PubMed ID: 15674402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sildenafil in neonatal pulmonary hypertension due to impaired alveolarisation and plexiform pulmonary arteriopathy.
    Chaudhari M; Vogel M; Wright C; Smith J; Haworth SG
    Arch Dis Child Fetal Neonatal Ed; 2005 Nov; 90(6):F527-8. PubMed ID: 16244212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Visual loss with erectile dysfunction medications.
    Wooltorton E
    CMAJ; 2006 Aug; 175(4):355. PubMed ID: 16870715
    [No Abstract]   [Full Text] [Related]  

  • 34. Optimisation of PDE5 inhibitor therapy in men with erectile dysfunction: converting "non-responders" into "responders".
    Eardley I
    Eur Urol; 2006 Jul; 50(1):31-3. PubMed ID: 16517052
    [No Abstract]   [Full Text] [Related]  

  • 35. Intravenous dipyridamole enhances the effects of inhaled nitric oxide and prevents rebound pulmonary hypertension in piglets.
    Foubert L; De Wolf D; Mareels K; Van Belleghem Y; Reyntjens K; Mortier E; Van Nooten G
    Pediatr Res; 2002 Nov; 52(5):730-6. PubMed ID: 12409521
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors.
    Corbin JD; Beasley A; Blount MA; Francis SH
    Biochem Biophys Res Commun; 2005 Sep; 334(3):930-8. PubMed ID: 16023993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Phosphodiesterase inhibitors in clinical practice. The present and the future. Part II].
    Baksheev BI; Kolomiets NM
    Klin Med (Mosk); 2007; 85(4):4-11. PubMed ID: 17564028
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sildenafil citrate therapy for pulmonary arterial hypertension.
    Galiè N; Ghofrani HA; Torbicki A; Barst RJ; Rubin LJ; Badesch D; Fleming T; Parpia T; Burgess G; Branzi A; Grimminger F; Kurzyna M; Simonneau G;
    N Engl J Med; 2005 Nov; 353(20):2148-57. PubMed ID: 16291984
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Central retinal vein occlusion in a patient after being commenced on sildenafil citrate for pulmonary arterial hypertension.
    Pinto LM; Morekar S; Mahashur AA
    Indian J Chest Dis Allied Sci; 2009; 51(4):249-51. PubMed ID: 20073379
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The efficacy and tolerability of sildenafil in patients with moderate-to-severe pulmonary hypertension.
    Bharani A; Mathew V; Sahu A; Lunia B
    Indian Heart J; 2003; 55(1):55-9. PubMed ID: 12760589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.